Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

• Status: Completed
• Trial end date: 2023-10-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University
• Treatments: Dulaglutide; Glucagon-Like Peptide-1 Receptor Agonists; Hypoglycemic Agents

Criteria

Inclusion Criteria:

• All adults aged 18 and above

• No minors involved in the study

• Diabetic Nephropathy defined as a urinary albumin-to-creatinine ratio ≥30 mg/g at least twice in three measurements within a period of 3-6 months

Exclusion Criteria:

• Patients with other types of kidney disease

• Urinary tract infection

• Type 1 diabetes